checkAd

    Genomic Vision  108  0 Kommentare First-half 2022 Results

    Regulatory News:

    Genomic Vision (the “Company” - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces its half-year financial results to June 30th, 20221. The H1 financial report is available in the Investors section of Genomic Vision’s website.

    H1 2022 results

    (in € thousands – IFRS)

    H1 2022

    H1 2021

    Revenue from sales

    511

    467

    Other revenue

    232

    235

    Total revenue from activity

    743

    702

    Current operating expenses

    (3,197)

    (3,066)

    Current operating loss

    (2,454)

    (2,364)

    Other operating expenses / income

    (57)

    50

    Operating loss

    (2,510)

    (2,314)

    Cost of financial debt and other financial expenses / income

    (40)

    (15)

    Net loss

    (2,568)

    (2,329)

    Revenue from sales totaled €511 thousand in the first half of 2022, growing by 9.4% compared with the first half of 2021. This growth was achieved by a more consolidated commercial offer, improvements in logistics and customer management, and by the sale of a scanner to the University of South Florida.
    Total revenue from activity, once other revenue is taken into account, grew by 5.8% to €743 thousand. Other revenue, corresponding to the Research Tax Credit, was €232 thousand.

    Current operating expenses grew by 4.3% to €3.2 million, and principally broke down as follows, in addition to the cost of sales:

    Seite 1 von 3


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Genomic Vision First-half 2022 Results Regulatory News: Genomic Vision (the “Company” - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces its half-year financial results to June …